The GLP-1 receptor agonist exendin-4 protected dopaminergic neurons by inhibiting microglial activation and MMP-3 expression, establishing a neuroprotective role for incretin drugs in Parkinson's-like neurodegeneration.
Key findingThe GLP-1 receptor agonist exendin-4 protected dopaminergic neurons by inhibiting microglial activation and MMP-3 expression, establishing a neuroprot
What the researchers found
The GLP-1 receptor agonist exendin-4 protected dopaminergic neurons by inhibiting microglial activation and MMP-3 expression, establishing a neuroprotective role for incretin drugs in Parkinson's-like neurodegeneration.
Why it matters
Relevant for peptide research.
How the study worked
research study.
What this study cannot tell us
See abstract.
How to read the evidence
emerging evidence.
When this study was published
Published in 2009.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
Common questions
What was studied?
What was found?
Read the original research
Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease.
The Journal of endocrinology, 202(3), 431-9
Citation
Kim, Sehee; Moon, Minho; Park, Seungjoon. (2009). Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease.. The Journal of endocrinology, 202(3), 431-9. https://doi.org/10.1677/JOE-09-0132